Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Kedudukan dalam Saham #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Harga Saham
$0.30780727
Modal Pasaran
$94.19M
Perubahan (1 hari)
-0.19%
Perubahan (1 tahun)
-34.73%
Negara
FR
Perdagangan Sensorion SA (ALSEN)

Kategori

Sejarah dividen untuk Sensorion SA (ALSEN)
Sensorion SA (simbol saham: ALSEN) telah membuat sejumlah 0 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): 0.00
Hasil dividen (TTM): 0
Pembayaran dividen untuk Sensorion SA (ALSEN) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (diselaraskan untuk pemecahan saham) Ubah
Tidak cukup data untuk tarikh yang disediakan.
Senarai semua pembayaran dividen
Tahun Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pembayaran dividen untuk syarikat serupa atau pesaing
Syarikat Jumlah pembayaran dividen Negara
52.00%
DK
0.00%
US
5.00%
US
29.00%
BE
0.00%
NL